Hyloris Pharmaceuticals Updates on Subscription Rights and Voting Securities

An update from Hyloris Pharmaceuticals SA ( (DE:52U) ) is now available.

Hyloris Pharmaceuticals announced a change in its remaining subscription rights, impacting the total number of securities carrying voting rights, which now stands at 28,000,374 ordinary shares. This update reflects the company’s strategic financial adjustments and could influence stakeholder decisions regarding the company’s stock and market participation.

More about Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA is a specialty biopharma company based in Liège, Belgium, focused on innovating, reinventing, and optimizing existing medications to address significant healthcare needs. The company leverages existing regulatory pathways like the FDA’s 505(b)2 in the U.S. to reduce development timelines and costs. Hyloris has a portfolio of 19 patented reformulated and repurposed medicines, with two products in early commercialization phases: Sotalol IV for atrial fibrillation and Maxigesic® IV, a non-opioid post-operative pain treatment.

YTD Price Performance: -26.05%

Average Trading Volume: 552

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €149.5M

For detailed information about 52U stock, go to TipRanks’ Stock Analysis page.